ASCO 2013: Cancer doctors convene; patients will benefit (VIDEO)

May 30, 2013 | by Tami Dennis

Annual meetings can be dreadful affairs, full of droning lectures and poorly conceived PowerPoint presentations that, when all is said and done, leave participants asking: What was the point of all that exactly? Not this one. The American Society of Clinical Oncology's annual meeting pulls together the nation’s best and brightest clinical oncologists – cancer doctors – in one place. There, they share knowledge, they discuss treatments, they ask questions, they review research and they learn. And then they take what they’ve learned back to their patients. “Even though we have access to the Internet and articles and the library and so forth, this allows an opportunity to actually interact with the people doing the research, to ask the questions that are difficult perhaps to answer, to get a better sense of what is the importance of a given new research finding in practical terms,” said City of Hope Chief Medical Officer Alexandra Levine, M.D., M.A.C.P. She further explains the impact of the meeting in the video above.Almost two dozen City of Hope researchers and physicians will be attending this year’s conference in Chicago, taking a plethora of their own research findings to share. Among the City of Hope offerings are these (for starters):
  • Hyaluronidase synthase 3 (HAS3) variant and anthracycline-related cardiomyopathy: A report from the Children’s Oncology Group. (Link) 
  • Comprehensive profiling of cardiac dysfunction in asymptomatic childhood cancer survivors (CCS) treated with anthracyclines. (Link) 
  • Phi-53: (NCI#7251): Phase I trial of belinostat (PXD101) in combination with 13-cis-retinoic acid (13c-RA) in advanced solid tumor malignancies — A California Cancer Consortium NCI/CTEP sponsored trial. (Link) 
  • Efficacy of the combination of ABT-888 (veliparib) and carboplatin in patients with BRCA-associated breast cancer. (Link)
  • A phase I study of an MVA vaccine targeting p53 in cancer. (Link) 
  • Efficacy of radioimmunotherapy-based conditioning with high-dose chemotherapy and autologous stem cell transplantation for transformed lymphoma. (Link) 
  • A first-in-human study of neural stem cells (NSCs) expressing cytosine deaminase (CD) in combination with 5-fluorocytosine (5-FC) in patients with recurrent high-grade glioma. (Link) 
  • A phase II trial assessing pazopanib (paz) as third-line therapy for metastatic renal cell carcinoma (mRCC): Clinical outcome and temporal analysis of molecular profile. (Link) 
  • Novel murine anti-HER2 monoclonal antibodies to induce apoptosis and regulate miR-21 in breast cancer cell. (Link) 
  • Measures of polypharmacy and chemotherapy toxicity in older adults with cancer. (Link) 
  • Impact of care at NCI-designated comprehensive cancer centers (NCICCC) on outcome in adolescents and young adults (AYA) with central nervous system tumors (CNSt). (Link) 
  • The Minneapolis-Manchester Quality of Life Instrument (MMQL): Reliability and validity of the Adult Form (AF). (Link) 
  • A feasibility study using a touchscreen tool in the AYA population. (Link)
  • L1-CAM as a predictor of survival in endometrial cancer: An analysis of The Cancer Genome Atlas (TCGA). (Link) 
  • Impact of cytoreductive nephrectomy on disease-specific survival (DSS) in the cytokine and targeted therapy eras: Age- and TNM-stage matched analysis of SEER data. (Link) 
  • Next-generation sequencing for genetic cancer risk assessment: Critical needs and perceptions of community clinicians. (Link) 
  • SWOG S1115: Randomized phase II clinical trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) versus mFOLFOX in patients with metastatic pancreatic cancer after prior chemotherapy. [TRIAL IN PROGRESS] (Link) 
  • Correlation of 64Cu-DOTA-trastuzumab positron emission tomography (PET) imaging with HER2 status by immunohistochemistry (IHC). [TRIAL IN PROGRESS] (Link) 
  • Metabolic syndrome and breast cancer: Effects of a 16-week combined exercise intervention. (Link) 
  • Developing a culturally and linguistically responsive survivorship care plan for breast cancer. (Link) 
  • Real-world treatment patterns in U.S. mRCC patients who fail two lines of targeted therapy. (Link) 
  • Extent of neutrophil (NTP) infiltration in benign lymph nodes (LNs) to predict survival in patients with muscle-invasive bladder cancer (MIBC). (Link) 
The average person might find some of these titles intimidating or, at the very least, dense. But from these findings will come new therapies, new approaches and new ways of thinking. And from that will come improved care for people with cancer. As annual meetings go, that’s a point we can all support. H. Chung So contributed to this article.


Back To Top

Search Blogs